Results 101 to 110 of about 14,793 (172)

Letter to the editor: When do rare events become expected in HIV drug resistance? [PDF]

Euro Surveill
El-Khatib Z, Wessman M, Sönnerborg A, Fonager J, Zoufaly A, Leierer G, Assadian O, Benka B, Ndeikoundam Ngangro N, Kantor R.   +9 more
europepmc   +1 more source

Clinical presentation and effectiveness of antiretroviral therapy in newly diagnosed people living with HIV before, during and after the COVID-19 pandemic. [PDF]

BMJ Public Health
Carbone A, Lombardi F, Tiecco G, Iannone V, Logiudice J, Salvo PF, Scoppettuolo G, Gerami R, Cesanelli F, Salvi M, Cingolani A, Castelli F, Di Giambenedetto S, Torti C, Quiros-Roldan E.   +14 more
europepmc   +1 more source

To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV? [PDF]

Curr HIV/AIDS Rep
Debroy P, Lake JE.
europepmc   +1 more source

HIV-1 integrase resistance in the context of antiretroviral therapy in paediatric patients ‒ Northeast Brazil. [PDF]

Braz J Infect Dis
Luz AL, Leal É, Lima K, Souza MM, Silva MLC, Lima MM, Sette PGT, Almeida YLM, Melo HRL.   +8 more
europepmc   +1 more source

Integrase inhibitor-based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection. [PDF]

Front Med (Lausanne)
Karaca B, Şener A, Kaptan F, Ece D, Örmen B, Caner A.   +5 more
europepmc   +1 more source

Time to Antiretroviral Therapy Initiation After HIV Diagnosis in the Integrase Strand Transfer Inhibitor Era - Nanjing City, Jiangsu Province, China, 2021-2024. [PDF]

China CDC Wkly
Ma C, Yang J, Liu A, Qian Z, Liu Z, Ge Y, Xu Y, Zhu Z, Wei H, Peng Z, Yin G, Hu Z.   +11 more
europepmc   +1 more source

The LEDGIN GS-9822 inhibits HIV-2 infection and enhances HIV-2 latency. [PDF]

Microbiol Spectr
Bruggemans A, Vansant G, Pellaers E, Van de Velde P, Christ F, Debyser Z.   +5 more
europepmc   +1 more source

HIV cure after HCT: 7 horses seem to be on the mark. [PDF]

Blood Adv
Camargo JF.
europepmc   +1 more source

HIV-1 drug resistance and associated risk factors in patients with antiretroviral therapy failure in Chongqing, China, 2019-2023. [PDF]

PLoS One
Zhang H, Wu P, Ye W.
europepmc   +1 more source

In Vitro Pharmacokinetic Properties of MK-2048, a Potent Drug Candidate for HIV Prevention. [PDF]

Viruses
Zheng R, Valicherla GR, Graebing PW, Zhang J, Hillier SL, Rohan LC.   +5 more
europepmc   +1 more source